Chun Chieh Lin1, Phillip J Gray1, Ahmedin Jemal1, Jason A Efstathiou2. 1. Surveillance and Health Services Research Program, Intramural Research, American Cancer Society, Atlanta, GA (CCL, AJ); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (PJG, JAE). 2. Surveillance and Health Services Research Program, Intramural Research, American Cancer Society, Atlanta, GA (CCL, AJ); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (PJG, JAE). jefstathiou@partners.org.
Abstract
BACKGROUND: Clinically lymph node-positive (cN+) prostate cancer (PCa) is an often-fatal disease. Its optimal management remains largely undefined given a lack of prospective, randomized data to inform practice. We sought to describe modern practice patterns in the management of cN+ PCa and assess the effect of adding radiation therapy (RT) to androgen deprivation therapy (ADT) on survival using the National Cancer Data Base. METHODS: Patients with cN+ PCa and without distant metastases diagnosed between 2004 and 2011 were included. Five-year overall survival for patients diagnosed between 2004 and 2006 and treated with ADT alone or ADT+RT were compared. Propensity score (PS) matching was used to balance baseline characteristics, and Cox multivariate regression analysis was used to estimate hazard ratios (HRs) for all-cause mortality. RESULTS: Of 3540 total patients, 32.2% were treated with ADT alone and 51.4% received ADT+RT. Compared with ADT alone, patients treated with ADT+RT were younger and more likely to have private insurance, lower comorbidity scores, higher Gleason scores, and lower PSA values. After PS matching, 318 patients remained in each group. Compared with ADT alone, ADT+RT was associated with a 50% decreased risk of five-year all-cause mortality (HR = 0.50, 95% CI = 0.37 to 0.67, two-sided P < .001; crude OS rate: 71.5% vs 53.2%). CONCLUSIONS: Using a large national database, we have identified a statistically significant survival benefit for patients with cN+ PCa treated with ADT+RT. These data, if appropriately validated by randomized trials, suggest that a substantial proportion of such patients at high risk for prostate cancer death may be undertreated, warranting a reevaluation of current practice guidelines.
BACKGROUND: Clinically lymph node-positive (cN+) prostate cancer (PCa) is an often-fatal disease. Its optimal management remains largely undefined given a lack of prospective, randomized data to inform practice. We sought to describe modern practice patterns in the management of cN+ PCa and assess the effect of adding radiation therapy (RT) to androgen deprivation therapy (ADT) on survival using the National Cancer Data Base. METHODS:Patients with cN+ PCa and without distant metastases diagnosed between 2004 and 2011 were included. Five-year overall survival for patients diagnosed between 2004 and 2006 and treated with ADT alone or ADT+RT were compared. Propensity score (PS) matching was used to balance baseline characteristics, and Cox multivariate regression analysis was used to estimate hazard ratios (HRs) for all-cause mortality. RESULTS: Of 3540 total patients, 32.2% were treated with ADT alone and 51.4% received ADT+RT. Compared with ADT alone, patients treated with ADT+RT were younger and more likely to have private insurance, lower comorbidity scores, higher Gleason scores, and lower PSA values. After PS matching, 318 patients remained in each group. Compared with ADT alone, ADT+RT was associated with a 50% decreased risk of five-year all-cause mortality (HR = 0.50, 95% CI = 0.37 to 0.67, two-sided P < .001; crude OS rate: 71.5% vs 53.2%). CONCLUSIONS: Using a large national database, we have identified a statistically significant survival benefit for patients with cN+ PCa treated with ADT+RT. These data, if appropriately validated by randomized trials, suggest that a substantial proportion of such patients at high risk for prostate cancer death may be undertreated, warranting a reevaluation of current practice guidelines.
Authors: Alberto Briganti; Giorgio Gandaglia; Nicola Fossati; Marco Moschini; Francesco Montorsi Journal: J Natl Cancer Inst Date: 2015-07-23 Impact factor: 13.506
Authors: Jeffrey J Tosoian; Michael A Gorin; Ashley E Ross; Kenneth J Pienta; Phuoc T Tran; Edward M Schaeffer Journal: Nat Rev Urol Date: 2016-10-11 Impact factor: 14.432
Authors: Kevin Shee; Claire M de la Calle; Albert J Chang; Anthony C Wong; Felix Y Feng; Alexander R Gottschalk; Peter R Carroll; Hao G Nguyen Journal: Adv Radiat Oncol Date: 2022-03-12
Authors: Rodolfo Borges Dos Reis; Alejandro Alías-Melgar; Andrés Martínez-Cornelio; Silvia P Neciosup; Juan Pablo Sade; Marcos Santos; Gustavo Martin Villoldo Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302
Authors: Nicholas D James; Melissa R Spears; Noel W Clarke; David P Dearnaley; Malcolm D Mason; Christopher C Parker; Alastair W S Ritchie; J Martin Russell; Francesca Schiavone; Gerhardt Attard; Johann S de Bono; Alison Birtle; Daniel S Engeler; Tony Elliott; David Matheson; Joe O'Sullivan; Delia Pudney; Narayanan Srihari; Jan Wallace; Jim Barber; Isabel Syndikus; Mahesh K B Parmar; Matthew R Sydes Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777